The Need for Innovative Testing Method
Diabetic Kidney Disease (DKD) is the leading global cause of End-Stage Kidney Disease (ESKD). Without early diagnosis and intervention, patients face irreversible kidney function decline, ultimately leading to dialysis or transplantation. Therefore, an "early and accurate" risk assessment is the crucial key to delaying disease progression and preventing further deterioration.
DNlite
The world's first in vitro diagnostic (IVD) test for predicting kidney disease progression. It effectively predicts the risk of rapid renal function decline.
Beyond Diagnosis, Foreseeing the Future
Transforming the medical paradigm from traditional "disease confirmation" to proactive "risk prediction." We empower healthcare professionals to intervene during the golden window, effectively delaying the need for dialysis and the onset of ESKD.
Clinical Outcomes
Simple Testing, Ultimate Precision
Providing a non-invasive (urine-based), highly accurate solution that elevates both the efficiency and quality of chronic disease management.
Patented Technologies
Global Reach & Regulatory Approvals
Global Breakthrough
The industry's first kidney disease prognostic product to obtain EU IVDR certification, setting the highest regulatory standard.
Global Network
Secured market authorization in over 42 countries, with a global network that fully covers the European Union.
Strategic Expansion
Successfully penetrated high-risk regions for Diabetic Kidney Disease (DKD), including major countries across Southeast Asia, the Middle East, and Latin America.
Global Patents
80
+
Market Authorizations
42
+
Countries
Latest News
Ready for the Next Step?
Discover DNlite
Where to Get Tested
City/County in Taiwan
Our Global Network
Region